蛛网膜下腔出血患者的氧化三甲胺(TMAO):一项前瞻性观察性研究
这项前瞻性观察性研究纳入34例自发性蛛网膜下腔出血(SAH)患者和108例神经、神经根或神经丛疾病对照,比较血浆TMAO水平,并检测SAH患者脑脊液TMAO。SAH组基线血浆TMAO(1.7 μmol/L)显著低于对照组(2.9 μmol/L);脑脊液可检出TMAO(0.4 μmol/L)且显著低于SAH组基线血浆;血浆与脑脊液TMAO正相关;15天观察期内TMAO水平无显著差异。
要点
- SAH患者基线血浆TMAO为1.7 μmol/L,显著低于神经、神经根或神经丛疾病对照组的2.9 μmol/L。
- SAH患者脑脊液TMAO为0.4 μmol/L,显著低于同组基线血浆水平,且血浆与脑脊液TMAO正相关。
- 15天观察期内血浆及脑脊液TMAO水平无显著差异,未发现SAH特征性TMAO模式。
核心结论
- 尽管事先假设TMAO较高者SAH风险更高,但入院时SAH患者血浆TMAO水平低于神经、神经根或神经丛疾病对照。
- 未发现SAH患者血浆TMAO水平的特征性模式。
研究设计与样本
- 前瞻性观察性研究,纳入初诊治疗后招募的自发性SAH患者及作为对照的神经、神经根或神经丛疾病患者。
- 所有患者招募时采集血样,SAH患者在重症监护室每日采样持续14天,并尽可能从现有脑室外引流采集脑脊液。
- 共34例SAH患者和108例对照患者参与研究。
主要发现
- SAH组基线血浆TMAO为1.7 μmol/L,显著低于对照组的2.9 μmol/L。
- 脑脊液可检出TMAO(0.4 μmol/L),显著低于SAH组基线血浆水平。
- 血浆与脑脊液TMAO水平呈正相关。
- 15天观察期内TMAO水平无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is suspected that microbiome-derived trimethylamine N-oxide (TMAO) may enhance platelet responsiveness and accordingly be thrombophilic. The purpose of this prospective observational study is to evaluate TMAO in patients with subarachnoid hemorrhage (SAH) and compare it with a control group. A secondary aim was to investigate TMAO in the cerebrospinal fluid (CSF) from SAH patients. This should provide a better understanding of the role of TMAO in the pathogenesis of SAH and its thrombotic complications. METHODS: The study included patients with diagnosed spontaneous SAH recruited after initial treatment on admission and patients with nerve, nerve root, or plexus disorders serving as controls. Blood samples were gathered from all patients at recruitment. Additionally, sampling of SAH patients in the intensive care unit continued daily for 14 days. The CSF was collected out of existing external ventricular drains whenever possible. RESULTS: Thirty-four patients diagnosed with SAH, and 108 control patients participated in this study. Plasma TMAO levels at baseline were significantly lower in the SAH group (1.7 μmol/L) compared to the control group (2.9 μmol/L). TMAO was detectable in the CSF (0.4 μmol/L) and significantly lower than in plasma samples of the SAH group at baseline. Plasma and CSF TMAO levels correlated positively. The TMAO levels did not differ significantly during the observation period of 15 days. CONCLUSIONS: Although we assumed that patients with higher TMAO levels were at higher risk for SAH a priori, plasma TMAO levels were lower in patients with SAH compared with control subjects with nerve, nerve root, or plexus disorders on admission to the hospital. A characteristic pattern of plasma TMAO levels in patients with SAH was not found.
引用
- Emonds JJ, Arlt F, Gaudl A, et al. Trimethylamine N-oxide (TMAO) in patients with subarachnoid hemorrhage: a prospective observational study. Acta Neurochir (Wien). 2023. PMID: 36695932. doi:10.1007/s00701-022-05485-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。